Bob Ehrlich of DTC Perspectives Should Do Better Research & Fact Checking Before He Calls Out Media for " Misreporting " on DTC Off-Label Promotion

I just received an email missive from Bob Ehrlich (@BobEhrlich_DTC), Chairman of DTC Perspectives, Inc., with the subject line " Media Misreporting Advertising Off-label Use. "Ehrlich said " I was shocked to see media stories saying DTC may expand to cover off label use. What! This erroneous idea came from an FDA open meeting held 11/16 to discuss off label use based on court cases allowing drug companies the right to discuss them. "WRONG!I first reported that the FDA was interested in hearing comments about off-label drug promotion to " patient and consumer audiences " back in September, 2016, after reading this in the Federal Register Notice (read "FDA May Have No Choice But to Allow Direct-to-Consumer Off-Label Drug Promotion" and find the noticehere):  " To what extent is it appropriate for firms to communicate information about unapproved uses of their approved/cleared medical products topatient and consumer audiences [my emphasis]? What disclosures and additional information would be needed to help ensure that a communication to lay audiences is truthful and non-misleading, given consumers ' lack of medical training and expertise in critically evaluating this type of information? "Obviously, Ehrlich did not bother to read the notice and only readsConsumer Reports, which published results of a survey it did on the topic and reported at the hearing. Regarding that, Ehrlich said:" The lay press thinks that FDA might open the floodgates of off label use in DTC. A publi...
Source: Pharma Marketing Blog - Category: Pharmaceuticals Tags: Bob Ehrlich DTC Advertising FDA off-label promotion Source Type: blogs